About

About Ymmunobio AG Ymmunobio is a Swiss Biotech Company founded in Basel in 2021 by experienced drug development experts and entrepreneurs, Katrin Rupalla & Peter Schiemann. The Ymmunobio Team is one of the most experienced in the industry with veteran drug development experts on board. Ymmunobio develops a Theranostics platform for treatment of solid tumors based on an invention by Dr. Mitsuro Kanda, School of Medicine, Nagoya University, Japan. The IP belongs completely to Ymmunobio. Founders, OKG Capital and private investors have supported Ymmunobio with CHF 1.7M to date. Ymmunobio’s asset is a First-in-Class TUMOR MARKER with OUTSTANDING PROPERTIES addressing unmet medical need: - Proven Presence in >13 Solid Tumors - Highest Prevalence in Patients up to 98% - Clear Presence in Tumor Tissue Only; No Presence in Normal Tissue 2 ADCs with positive results in vitro and in vivo 2 Radiopharmaceuticals in co-development with PSI* fully supported by Innosuisse 2 Bi-specific T-cell engager antibodies (BiTE) in lead optimization Raising CHF 10M to bring the lead ADC to IND ready stage Exit Scenarios: - IND ready stage including Tox studies and CMC scale up - PoC in humans (dose escalation and expansion cohort/basked trial) Seeking Co-Development partnership with Industry or investor support *PSI: Paul-Scherrer-Institute